Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
16 Sep, 26
ERS 2026
Key updates on Chronic Obstructive Pulmonary Disease (COPD) presented at ERS 2026 at Barcelona, Spain from 5th - 9th September, 2026.
8 Sep, 26
This 2026 GOLD report is an evidence-based strategy document that provides key insights on prevention, diagnosis and management of COPD.
10 Sep, 26
A 73-year-old man with COPD presented with worsening breathlessness, wheezing, and yellow sputum. Imaging revealed pneumonia and a right lung tumor in the setting of AECOPD. Click here to read the treatment.
28 Aug, 26Chest
- Eosinophilic AE-COPD (blood eosinophils ≥300/μL within 3 days before to 1 day after the event), was associated with a significantly lower 1-year risk of major adverse cardiovascular events vs non-eosinophilic AE-COPD
- Eosinophilic AE-COPD was linked to reduced risks of heart failure, myocardial infarction, stroke, arrhythmias, and mortality, highlighting eosinophil count as a valuable cardiovascular risk biomarker.
28 Aug, 26Diabetes Care.
- 4693 women followed for 10-14 yrs postpartum, showed GDM these subtypes: insulin-deficient (3%), insulin-resistant (9%), mixed-defect (1.6%), & unclassified (0.7%)
- Insulin-deficient, insulin-resistant, & mixed-defect GDM were linked to higher risk of prediabetes/diabetes vs no GDM (RR 2.14 to 2.88), metabolic syndrome, & higher predicted CVD risk; dyslipidemia was significant only with insulin-resistant GDM.
27 Aug, 26Lancet Prim Care.
- Amongst a multinational cohort of 5.84 million adults initiating antihypertensive therapy, 1.9% suffered with ADHD
- ADHD was associated with higher risk of MACE (HR:1.31, 95% CI 1.18-1.45) & all-cause mortality (HR:2.83, 95% CI 2.07-3.87)
- After adjustment for psychiatric/cardiometabolic comorbidities, risks attenuated
- ADHD medication was not associated with MACE (HR 1.00) or mortality (HR 0.96)
7 Sep, 26
Featured
Patient Education
11 Sep, 26
11 Sep, 26
11 Sep, 26
8 Sep, 26
